HC Wainwright Increases Amicus Therapeutics (NASDAQ:FOLD) Price Target to $20.00

Amicus Therapeutics (NASDAQ:FOLD) had its price target increased by equities research analysts at HC Wainwright from $18.00 to $20.00 in a research note issued on Tuesday, Briefing.com Automated Import reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s target price points to a potential upside of 108.99% from the company’s current price.

FOLD has been the topic of several other reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Amicus Therapeutics in a report on Thursday, October 17th. ValuEngine cut Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 8th. Cowen set a $31.00 target price on Amicus Therapeutics and gave the company a “buy” rating in a report on Thursday, October 10th. Zacks Investment Research upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $9.25 target price on the stock in a report on Monday, November 4th. Finally, BidaskClub upgraded Amicus Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, November 5th. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Amicus Therapeutics has an average rating of “Buy” and a consensus price target of $17.97.

Shares of FOLD traded up $0.22 during midday trading on Tuesday, reaching $9.57. 3,073,900 shares of the stock were exchanged, compared to its average volume of 2,514,296. The stock’s 50 day simple moving average is $8.40 and its 200 day simple moving average is $10.76. Amicus Therapeutics has a twelve month low of $7.11 and a twelve month high of $14.61. The company has a market cap of $2.43 billion, a P/E ratio of -7.20 and a beta of 1.58. The company has a quick ratio of 6.97, a current ratio of 6.20 and a debt-to-equity ratio of 0.36.

Amicus Therapeutics (NASDAQ:FOLD) last announced its earnings results on Monday, November 11th. The biopharmaceutical company reported ($0.24) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.32) by $0.08. Amicus Therapeutics had a negative return on equity of 62.61% and a negative net margin of 216.02%. The business had revenue of $48.80 million for the quarter, compared to analysts’ expectations of $48.05 million. During the same period in the prior year, the business posted ($0.84) earnings per share. The firm’s revenue was up 136.9% on a year-over-year basis. As a group, analysts predict that Amicus Therapeutics will post -1.27 earnings per share for the current year.

In other Amicus Therapeutics news, CEO John F. Crowley sold 20,000 shares of the stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $9.02, for a total transaction of $180,400.00. Following the transaction, the chief executive officer now directly owns 755,694 shares in the company, valued at approximately $6,816,359.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO John F. Crowley sold 14,500 shares of the stock in a transaction that occurred on Friday, October 11th. The stock was sold at an average price of $8.01, for a total value of $116,145.00. Following the transaction, the chief executive officer now owns 735,694 shares in the company, valued at $5,892,908.94. The disclosure for this sale can be found here. Insiders have sold a total of 54,500 shares of company stock worth $497,545 over the last 90 days. Company insiders own 2.50% of the company’s stock.

Several institutional investors have recently bought and sold shares of the business. Point72 Hong Kong Ltd acquired a new position in shares of Amicus Therapeutics during the second quarter worth approximately $49,000. US Bancorp DE raised its position in shares of Amicus Therapeutics by 50.9% during the second quarter. US Bancorp DE now owns 4,896 shares of the biopharmaceutical company’s stock worth $61,000 after purchasing an additional 1,651 shares during the period. Meeder Asset Management Inc. acquired a new position in shares of Amicus Therapeutics during the second quarter worth approximately $73,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. acquired a new position in shares of Amicus Therapeutics during the second quarter worth approximately $122,000. Finally, Weil Company Inc. acquired a new position in shares of Amicus Therapeutics during the second quarter worth approximately $125,000.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.

Featured Story: Understanding the two types of arbitrage

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.